KLK3 and metastatic neoplasm: These findings are particularly important given the increase in incidence of distant stage disease among men aged 50 to 69 years, presumably the result of United States Preventive Services Task Force recommendation discouraging routine prostate specific antigen (PSA) screening.3, 13, 14 This investigation is one of the first to report stark differences in treatment uptake by race in a population‐based cohort of men with advanced prostate cancer including the most current treatment modalities for men diagnosed with metastatic disease.